Although the exact pathophysiological contribution of osteopontin and osteoprotegrin in patients with PAD is still to be elucidated, it can be hypothesized that these parameters may serve as possible biomarkers of restenosis after endovascular revascularization. This evidence concerns the gene SPP1 and peripheral arterial disease.